COMMON STOCK PURCHASE WARRANT DERMATA THERAPEUTICS, INC.Common Stock Purchase Warrant • August 6th, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ____, 20261 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Dermata Therapeutics, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), up to ___ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder o
DERMATA THERAPEUTICS, INC. and DIRECT TRANSFER, LLC, as Warrant Agent Warrant Agency Agreement Dated as of __, 2021Warrant Agency Agreement • August 6th, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of ____, 2021 (“Agreement”), between Dermata Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Direct Transfer LLC (the “Warrant Agent”).
SHARES OF COMMON STOCK AND ___________ WARRANTS TO PURCHASE ___________ SHARES OF COMMON STOCK OF DERMATA THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 6th, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Dermata Therapeutics, Inc., a company incorporated under the laws of Delaware (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
SECOND AMENDMENT TO LICENSE AND SETTLEMENT AGREEMENTLicense and Settlement Agreement • August 6th, 2021 • Dermata Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LICENSE AND SETTLEMENT AGREEMENT (“Second Amendment”) is made, effective as of the date executed below by both parties, by and between Villani, Inc., a Delaware corporation with mailing address of 220 Newport Center Dr., Suite 11-578, Newport Beach CA 92660 (the “Licensor”) and Dermata Therapeutics, Inc., a Delaware corporation as successor to Dermata Therapeutics, LLC a Delaware limited liability company having a principal place of business at 3525 Del Mar Heights Rd., #322, San Diego, California 92130 (“Dermata”), and Maria Villani exclusively for purposes of the Mutual Release and Settlement herein. Licensor and Dermata may each be referred to herein individual as a “Party” and collectively as the “Parties.” All defined terms in the License Agreement (as amended above) shall have the same meanings in this Second Amendment.
